TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03815578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination
Description: * Number of painful joints,~* Number of swollen joints,~* Patient Global assessment VAS (0 - 100)~* and Physician Global assessment VAS (0 - 100)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain assessment
Description: * Pressure Pain Thresholds (PPTs),~* Mechanical Temporal Summation (MTS)~* and Diffuse Noxious Inhibitory Control (DNIC)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 18 ml whole blood for ELISA analysis and miRNAs detection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Reported Outcomes
Description: * Health Assessment Questionnaire (HAQ),~* Rheumatoid Arthritis Impact of Disease score (RAID),~* Daily joint pain intensity VAS (0-100),~* Hospital Anxiety and Depression scale~* and Coping Strategy Questionnaire.
Study: NCT04416230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: massage
Description: The massage included 30 minutes of gentle friction, kneading, stroking, and passive touch on the infant's accessible upper extremities, lower extremities, head, face, and back.
Study: NCT03431233

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-enriched bar, commercial cereal bar, or water
Description: Protein enriched bar, commercial cereal bar, or water will be provided 15 minutes before breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-enriched bar, commercial cereal bar, or water
Description: Protein enriched bar, commercial cereal bar, or water will be provided 15 minutes before breakfast.
Study: NCT00934102

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Narafilcon A contact lens
Description: Investigational, silicone hydrogel, spherical soft contact lens
Study: NCT03430076

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: revascularization
Description: open revascularization for below-knee popliteal in the absence of an suitable autologous vein with PTFE.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: revascularization
Description: open revascularization for below-knee popliteal in the absence of an suitable autologous vein with PTFE.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Propaten®
Description: Propaten®

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crude PTFE
Description: Crude PTFE
Study: NCT00948467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-733
Description: The Initial Escalation Stage will enroll approximately 30 patients with advanced nonhematologic malignancies. TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.~The Expansion Stage will enroll approximately 30 patients with advanced metastatic melanoma. The recommended phase 2 dose determined in the Initial Escalation Stage of TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.
Study: NCT02073383

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary brachial plexus block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary brachial plexus block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary brachial plexus block
Study: NCT05694377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electroencephalography-based neurofeedback (EEG-NFB)
Description: The EEG-NFB training program will involve nine training sessions (three times a week over a 3-week period) each lasting 30 min. EEG-NFB training will be conducted with ProComp Infiniti Encoder and BioGraph Infiniti Software v.5.1.3. The training protocol will be set to decrease the EEG TBR value. For the 12 training sessions, all participants will be subjected the same EEG-NFB protocol at C3 electrode. The EEG-NFB training sessions consists of a 20-s baseline period (i.e., with no feedback), 30-min feedback presentation, and another 20-s baseline period. Subjects will be seated in front of a computer screen and animations will be used as feedback; the animation starts when the subject is sufficiently focused for 20 s. Three 10-min animations (flying duck, roller coaster ride, and moving ball) will be shown to the subject during each EEG-NFB training session. The raw EEG signal, TBR value over time, EEG signal noise, and EEG theta and beta wave amplitudes will be recorded.
Study: NCT00811642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: 400mg BID oral suspension for 12 weeks
Study: NCT02306031

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prescribe ARTIFICIAL TEAR
Description: From one week before surgery, and control group received artificial tear (Sina Darou Laboratories Company, Tehran, Iran) as a placebo every 6 hours. Theses drops continued up to 6 weeks with the same dose after operations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prescribe diclofenac sodium drop 0.1%
Description: From one week before surgery, case group received diclofenac sodium drop 0.1% (Sina Darou Laboratories Company, Tehran, Iran) every 6 hours.Theses drops continued up to 6 weeks with the same dose after operations
Study: NCT02727530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VISCERAL MANUAL THERAPY-ADVICES
Description: The subjects of this group will receive an amount of two sessions of visceral manual therapy that will be applied within two weeks. In the first session will be applied procedures in the most superficial body structures. And, in the second session will be applied procedures in the most deep body structures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADVICES
Description: Advices for parents to improve the management of infant colic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADVICES
Description: Advices for parents to improve the management of infant colic
Study: NCT02310087

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: astaxanthin with vitamin E
Description: Four tablets of 4 mg astaxanthin with 10 mg vitamin E daily, taken at once. Daily dose is 16 mg astaxanthin with 40 mg vitamin E. Continuously for three months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four tablets of placebo daily, taken at once. Continuously for three months.
Study: NCT02867553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Multi-fields radiotherapy
Study: NCT01167387

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PREOP
Description: a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrine; 240 mOsm/L) in dose of 800 mL

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: The control group will receive plain water with the same volume and timing of treatment.
Study: NCT03048136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study: NCT00934102

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon A contact lens
Description: Commercially marketed, silicone hydrogel, spherical soft contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Galyfilcon A contact lens
Description: Commercially marketed, silicone hydrogel, spherical soft contact lens
Study: NCT02304926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: simvastatin (40 mg/day) for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: ezetimibe (10 mg/day) for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin + Ezetimibe
Description: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period
Study: NCT03048136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study: NCT02304926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin + Ezetimibe
Description: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period
Study: NCT02673255

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus and Diphtheria (Td) Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus and Diphtheria (Td) Vaccine
Study: NCT05651347

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, visually identical to the melatonin tablets, but containing no active ingredient are administered three times a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 10 MG
Description: Melatonin 10 mg tablets will be administered three times a day, up to a maximum of 30 mg daily
Study: NCT01510327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROMUS Element Everolimus-Eluting Coronary Stent System
Description: PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thienopyridine
Description: Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
Study: NCT00801814

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PGX)
Description: 2.5 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PGX)
Description: 2.5 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PGX)
Description: 2.5 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PG)
Description: 5.0 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PG)
Description: 5.0 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX (PG)
Description: 5.0 grams of PGX
Study: NCT00621621

Intervention type: DEVICE
Group type: OTHER
Intervention: Freezor® Cardiac Cryoablation Catheter CryoConsole System
Description: cryoablation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freezor® Cardiac Cryoablation Catheter CryoConsole System
Description: cryoablation
Study: NCT02153879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: fenofibrate 145/day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin plus laropiprant
Description: Niacin 2 g/day plus Laropiprant for 12 weeks
Study: NCT00801814

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX
Description: 7.5 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX
Description: 7.5 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyGlycopleX
Description: 7.5 grams of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 0g of PGX

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 0g of PGX
Study: NCT01306578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG
Description: Intravenous Immune Globulin at a dose 0f 0.4 g/kg/day for 5 consecutive days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasma Exchange
Description: Five sessions of plasma exchange, single plasma volume each, for 5 consecutive days
Study: NCT04416230

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: quiet time
Description: During quiet time, the infant received a 30 minute quiet time (QT) period during which non-essential caregiving tasks were restricted. During QT, clinicians were asked to avoid direct clinical caregiving activities, i.e. activities requiring physical contact with the infant.
Study: NCT03093688

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of iNKT cells and CD8+T cells
Description: The eligible patients receive twice infusions of iNKT cells(1E8\~1E10) and CD8+T cells(1E7\~1E9) in one course of treatment.
Study: NCT04738305

Intervention type: OTHER
Group type: OTHER
Intervention: Dignity Therapy
Description: The Italian version Dignity Therapy intervention (Chochinov HM 2015) has been delivered. Intervention questions were not previously delivered to patients.~DT interview was provided to patients by Specifically trained Nurses. Interviews were audio-recorded and transcribed then revised by the patients to develop the final Generativity Document. Generativity Document was delivered to patients that could share it with their loved ones.
Study: NCT01829243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Milnacipran

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03206164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asynchronous, eLearning Intervention
Description: 20 CBOs with 3-member team (n= 30) will be recruited and placed into either the experimental or the comparison group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asynchronous, eLearning Intervention
Description: 20 CBOs with 3-member team (n= 30) will be recruited and placed into either the experimental or the comparison group.
Study: NCT02802046

Intervention type: RADIATION
Intervention: Computed tomographic angiography of coronary artery

Intervention type: RADIATION
Intervention: Computed tomographic angiography of coronary artery
Study: NCT04003350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Patients are given, for up to 4 weeks, Oxycodone 5m PRN every four hours (up to 30 tablets)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Patients are given, for up to 4 weeks, Oxycodone 5m PRN every four hours (up to 30 tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Patients are given, for up to 4 weeks, Tramadol 50mg PRN every 6 hours (up to 30 tablets)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Patients are given, for up to 4 weeks, Tramadol 50mg PRN every 6 hours (up to 30 tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol
Description: Tylenol 1000 mg: take as needed every 8 hours
Study: NCT04598256

Intervention type: PROCEDURE
Intervention: Endoscopic procedure
Description: Esophagogastroscopy and colonoscopy
Study: NCT00608569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Two tablets (200-mg lopinavir and 50 mg ritonavir in each tablet), taken orally twice daily
Study: NCT04003350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam 15 mg as need once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: •Gabapentin 200 mg with morning and evening Tylenol dose
Study: NCT00608569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir
Description: Two tablets (200-mg lopinavir and 50 mg ritonavir in each tablet), taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: 200-mg emtricitabine and 300 mg tenofovir disoproxil fumarate in each tablet, taken orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: 200-mg emtricitabine and 300 mg tenofovir disoproxil fumarate in each tablet, taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300-mg tablet taken orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Description: 300-mg tablet taken orally once daily
Study: NCT04003350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metaxalone
Description: Metaxalone 800mg TID
Study: NCT00608569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: 300-mg tablet taken orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: 300-mg tablet taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: 200-mg tablet taken orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine
Description: 200-mg tablet taken orally once daily
Study: NCT03829878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP101
Description: Orally administered donor derived full spectrum microbiota

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for CP101
Study: NCT03190733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: ATG will be intravenously infused via a central venous catheter in 4 or 5 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include fludarabine (Flu), busulfan (Bu),cyclophosphamide (Cy). All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF) for aGVHD prevention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: ATG will be intravenously infused via a central venous catheter in 4 or 5 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include fludarabine (Flu), busulfan (Bu),cyclophosphamide (Cy). All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF) for aGVHD prevention.
Study: NCT04064008

Intervention type: DEVICE
Intervention: PROFEMUR® Z Revision Femoral Stem
Description: Total Hip Total Hip Arthroscopy
Study: NCT01467778

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELAPR
Description: ELAPR implant product is under development for mid to deep dermal implantation for the treatment of the symptoms of skin aging including the correction of moderate to sever facial wrinkles and folds, such as nasolabial folds and skin abnormalities such as scars.
Study: NCT00801814

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Second Control
Description: 0g of PGX
Study: NCT01467778

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELAPR
Description: ELAPR implant product is under development for mid to deep dermal implantation for the treatment of the symptoms of skin aging including the correction of moderate to sever facial wrinkles and folds, such as nasolabial folds and skin abnormalities such as scars.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELAPR
Description: ELAPR implant product is under development for mid to deep dermal implantation for the treatment of the symptoms of skin aging including the correction of moderate to sever facial wrinkles and folds, such as nasolabial folds and skin abnormalities such as scars.
Study: NCT04003350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20mg
Description: Esomeprazole 20mg daily
Study: NCT00296647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine patch
Description: Decreasing dosages from 21 to 7 mg over 12 week period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine patch
Description: Decreasing dosage from 21 to 7 mg over 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine lozenge
Description: 4 mg nicotine lozenge: dosage according to package directions for 16 weeks
Study: NCT01467778

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ELAPR
Description: ELAPR implant product is under development for mid to deep dermal implantation for the treatment of the symptoms of skin aging including the correction of moderate to sever facial wrinkles and folds, such as nasolabial folds and skin abnormalities such as scars.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELAPR
Description: Implant area of the medial aspect of the upper arm along the posterior line of the bicep is to be selected where there are no pigmentations or moles. Injections will be marked with a tattoo and placed at 2 cm intervals. The order is to be from proximal to distal control, ELAPR001, ELAPR002, ELAPR003

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELAPR
Description: Implant area of the medial aspect of the upper arm along the posterior line of the bicep is to be selected where there are no pigmentations or moles. Injections will be marked with a tattoo and placed at 2 cm intervals. The order is to be from proximal to distal control, ELAPR001, ELAPR002, ELAPR003

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELAPR
Description: Implant area of the medial aspect of the upper arm along the posterior line of the bicep is to be selected where there are no pigmentations or moles. Injections will be marked with a tattoo and placed at 2 cm intervals. The order is to be from proximal to distal control, ELAPR001, ELAPR002, ELAPR003

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ELAPR
Description: Implant area of the medial aspect of the upper arm along the posterior line of the bicep is to be selected where there are no pigmentations or moles. Injections will be marked with a tattoo and placed at 2 cm intervals. The order is to be from proximal to distal control, ELAPR001, ELAPR002, ELAPR003
Study: NCT03448874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seal-G MIST System
Description: Seal-G MIST is an adjunct device that will be applied adjunctively to cover standard closure techniques.
Study: NCT00668356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: didanosine
Description: 28 days 400 mg/m2/day during the meal 28 days 240 mg/m2/day during fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: didanosine
Description: 28 days 240 mg/m2/day during fasting 28 days 400 mg/m2/day during the meal